Hepion Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Apr 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 8, 2025
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues | $— | $— |
| Costs and expenses: | ||
| Research and development | 11,847,348 | 35,639,656 |
| General and administrative | 7,499,230 | 9,618,298 |
| Asset impairment loss | — | 3,190,000 |
| Total operating expenses | 19,346,578 | 48,447,954 |
| Loss from operations | (19,346,578) | (48,447,954) |
| Other income (expense): | ||
| Interest expense, net | (1,247,313) | (9,465) |
| Write-off related party note receivable | (600,000) | — |
| Change in fair value of contingent consideration and derivative financial instruments | 7,599,263 | (877,645) |
| Inducement expense | (2,567,044) | — |
| Loss before income taxes | (16,161,672) | (49,335,064) |
| Income tax benefit (expense) | 2,969,252 | 409,022 |
| Net loss | $(13,192,420) | $(48,926,042) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 122,894 | 79,416 |
| Net loss per common share: (see Note 11) | ||
| Basic and diluted | $(107.35) | $(616.07) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.